Colorectal Cancer Molecular Biology Moves into Clinical Practice

Overview

Journal Gut

Specialty Gastroenterology

Date 2010 Oct 6

PMID 20921207

Citations 145

Authors

Colin C Pritchard

William M Grady

Affiliations

Soon will be listed here.

Abstract

The promise of personalised medicine is now a clinical reality, with colorectal cancer genetics at the forefront of this next major advance in clinical medicine. This is no more evident than in the recent advances in testing of colorectal cancers for specific molecular alterations in order to guide treatment with the monoclonal antibody therapies cetuximab and panitumumab, which target the epidermal growth factor receptor. In this review, genetic mechanisms of colorectal cancer and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers) and the prediction of treatment responses (predictive markers) are examined.

Citing Articles

Predictive role of [F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients.

Ali M, Zahra O, Morsi M, El Safwany M, El Feky S EJNMMI Rep. 2024; 8(1):42.

PMID: 39722096 PMC: 11669641. DOI: 10.1186/s41824-024-00233-5.

Functions of Circular RNA in Human Diseases and Illnesses.

Gu A, Jaijyan D, Yang S, Zeng M, Pei S, Zhu H Noncoding RNA. 2023; 9(4).

PMID: 37489458 PMC: 10366867. DOI: 10.3390/ncrna9040038.

Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer.

Kan C, Pei X, Yeung M, Jin N, Ng S, Tsang H Int J Mol Sci. 2023; 24(13).

PMID: 37446204 PMC: 10341751. DOI: 10.3390/ijms241311026.

Comprehension of rectosigmoid junction cancer molecular features by comparison to the rectum or sigmoid colon cancer.

Zhu Q, Zhu C, Zhang X, Zhu X, Chen Z, Gu D J Gastrointest Oncol. 2023; 14(3):1307-1319.

PMID: 37435233 PMC: 10331759. DOI: 10.21037/jgo-23-120.

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.

Strickler J, Yoshino T, Stevinson K, Eichinger C, Giannopoulou C, Rehn M Oncologist. 2023; 28(11):e981-e994.

PMID: 37432264 PMC: 10628573. DOI: 10.1093/oncolo/oyad138.

References

Engstrom P, Arnoletti J, Benson 3rd A, Chen Y, Choti M, Cooper H . NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009; 7(8):778-831. DOI: 10.6004/jnccn.2009.0056. View

Maley C, Galipeau P, Finley J, Wongsurawat V, Li X, Sanchez C . Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006; 38(4):468-73. DOI: 10.1038/ng1768. View

Hoskins J, Goldberg R, Qu P, Ibrahim J, McLeod H . UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007; 99(17):1290-5. DOI: 10.1093/jnci/djm115. View

Ogino S, Nosho K, Kirkner G, Shima K, Irahara N, Kure S . PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009; 27(9):1477-84. PMC: 2659340. DOI: 10.1200/JCO.2008.18.6544. View

Iacopetta B, Kawakami K, Watanabe T . Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?. Int J Clin Oncol. 2008; 13(6):498-503. DOI: 10.1007/s10147-008-0854-3. View

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D . KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009; 101(4):715-21. PMC: 2736831. DOI: 10.1038/sj.bjc.6605177. View

Zauber P, Sabbath-Solitare M, Marotta S, Bishop D . Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003; 56(3):137-40. PMC: 1187308. DOI: 10.1136/mp.56.3.137. View

Shia J, Klimstra D, Li A, Qin J, Saltz L, Teruya-Feldstein J . Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 2005; 18(10):1350-6. DOI: 10.1038/modpathol.3800417. View

Boland C, Thibodeau S, Hamilton S, Sidransky D, Eshleman J, Burt R . A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58(22):5248-57. View

10.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

11.

Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C . Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003; 63(18):5738-44. View

12.

Artale S, Sartore-Bianchi A, Veronese S, Gambi V, Sarnataro C, Gambacorta M . Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008; 26(25):4217-9. DOI: 10.1200/JCO.2008.18.7286. View

13.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26(35):5705-12. DOI: 10.1200/JCO.2008.18.0786. View

14.

Grady W . Genomic instability and colon cancer. Cancer Metastasis Rev. 2004; 23(1-2):11-27. DOI: 10.1023/a:1025861527711. View

15.

Hinoue T, Weisenberger D, Pan F, Campan M, Kim M, Young J . Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One. 2009; 4(12):e8357. PMC: 2791229. DOI: 10.1371/journal.pone.0008357. View

16.

Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J . BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer. 2005; 104(5):952-61. DOI: 10.1002/cncr.21266. View

17.

Itzkowitz S, Jandorf L, Brand R, Rabeneck L, Schroy 3rd P, Sontag S . Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2006; 5(1):111-7. DOI: 10.1016/j.cgh.2006.10.006. View

18.

Jhawer M, Goel S, Wilson A, Montagna C, Ling Y, Byun D . PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008; 68(6):1953-61. PMC: 3972216. DOI: 10.1158/0008-5472.CAN-07-5659. View

19.

Popat S, Hubner R, Houlston R . Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23(3):609-18. DOI: 10.1200/JCO.2005.01.086. View

20.

Zhang L . Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn. 2008; 10(4):301-7. PMC: 2438197. DOI: 10.2353/jmoldx.2008.080062. View